Emerging treatments in multiple sclerosis: Azathioprine and Mofetil

Multiple Sclerosis

Volumn 1, Issue 6, 1996, Pages 379-384

  Confavreux, C ^a   Moreau, T ^a  

^a Hopital de l'Antiquaille   (France)

Author keywords

Azathioprine; Mofetil; Multiple sclerosis; Treatment

Indexed keywords

AZATHIOPRINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

DOSE RESPONSE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MYCOPHENOLIC ACID;

EID: 0030177996     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100620     Document Type: Article

References (27)

1. Hintzen RQ, Polman CH, Lucas CJ, Van Lier RAW. (1992) Multiple sclerosis: immunological findings and possible implications for therapy. J Neuroimmunol 39: 1-10.
2. Adorini I et al. (1990) New perspectives on immunointervention in autoimmune diseases. Immunology Today 11: 383-386.
3. The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
4. Reingold SC. (1993) Advances in the understanding and treatment of multiple sclerosis. Boston, Massachussets, USA, 28-29 October 1992. J Neuroimmunol 44: 221-224.
5. Allison AC, Kowalski WJ, Muller CD, Eugui EM. (1993) Mechanisms of action of mycophenolic acid. Annals of the New York Academy of Sciences 696: 63-87.
6. Aimard G, Girard PF, Raveau J. (1966) Sclérose en plaques et processus d'auto-immunisation. Traitement par les anti-mitotiques. Lyon Médical 215: 345-352.
7. Elion GB. (1989) The purine path to chemotherapy. Science 244: 41-47.
8. Yudkin PL et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338: 1051-1055.
9. Ellison GW et al. (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39: 1018-1026.
10. British and Dutch multiple sclerosis azathioprine trial group. (1988) Double-masked trial of azathioprine in multiple sclerosis. Lancet ii: 179-183.
11. Goodkin DE et al. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 41: 20-25.
12. Kurtzke JF. (1965) Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology 15: 654-661.
13. Hauser SL et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Eng J Med 308: 173-180.
14. Kappos L et al. (1988) Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology 30: 299-302.
15. Cavazzuti M, Tassone G, Canafoglia L, Merelli E. (1995) Lesion load quantification in serial MRI of MS patients under azathioprine treatment: a retrospective analysis. J Neuroimmunol Supplement 1: 16.
16. Miller DH et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiat 54: 683-688.
17. Aimard G et al. (1983) Etude de 213 cas de Sclérose en Plaques traités par l'Azathioprine de 1967 à 1982. Rev Neurol (Paris) 139: 509-513.
18. Chocair PR, Duley JA, Simmonds HA, Cameron JS. (1992) The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53: 1051-1056.
19. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. (1992) Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2: 148-159.
20. Naber AH, Van Haelst U, Yap SH. (1991) Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 12: 94-99.
21. Gane E et al. (1994) Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 20: 88-94.
22. Johnson PJ, McFarlane IG, Williams R. (1995) Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333: 958-963.
23. Krikorian JG et al. (1978) Malignant neoplasms following cardiac transplantion. JAMA 240: 639-643.
24. Kinlen LJ, Peto J, Doll R, Shiel AGR. (1981) Cancer in patients treated with immunosuppressive drugs. Brit Med J 282: 474.
25. Sheil AGR, Flavel S, Disney APS, Mathew TH. (1985) Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc 17: 1685-1688.
26. Penn I. (1990) Cancers complicating organ transplantation. N Engl J Med 323: 1767-1769.
27. Preston DS, Stern RS. (1992) Nonmelanoma cancers of the skin. N Engl J Med 327: 1649-1662.